BioCentury
ARTICLE | Clinical News

Dutrebis lamivudine/raltegravir regulatory update

January 26, 2015 8:00 AM UTC

EMA’s CHMP recommended approval of Dutrebis lamivudine/raltegravir to treat HIV-1 infection in patients ages ³6 and weighing ³30 kg. According to CHMP, Dutrebis reduces the daily pill burden while ret...